[A25-33] Nirsevimab (prevention of RSV lower respiratory tract disease) – Benefit assessment according to §35a Social Code Book V
Last updated 02.06.2025
Project no.:
A25-33
Commission:
Commission awarded on 18.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in children during their first RSV season who are not addressed in the therapeutic advice on RSV antibodies
Indication of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-33
| Project no. | Title | Status |
|---|---|---|
| A24-82 | Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease, 2nd. RSV season) – Benefit assessment according to §35a Social Code Book (SGB) V | Commission completed |
| A24-27 | Nirsevimab (prevention of RSV disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |